Table 5.
Adherence to Follow-Up Among Patients with a Negative Baseline Screen
| Lung-RADS 1 | |||
|
Black Patients n = 85 |
White Patients n = 97 |
p-value | |
| Mean Age ± SD | 63.8 ± 5.7 | 64.7 ± 6.0 | 0.287 |
| Sex | |||
| • Female | 54 (63.5%) | 43 (44.3%) | 0.010 |
| • Male | 31 (36.5%) | 54 (55.7%) | |
| Overall adherencea, n (%) | 15 (17.6%) | 19 (19.6%) | 0.738 |
| Time to follow-up CTb, mean mos ± SD | 13.3 ± 1.0 | 12.9 ± 2.2 | 0.493 |
| Timely adherencec, n (%) | 5 (33.3%) | 11 (57.9%) | 0.154 |
| Lung-RADS 2 | |||
|
Black Patients n = 81 |
White Patients n = 144 |
p-value | |
| Mean Age ± SD | 63.7 ± 6.2 | 63.8 ± 6.0 | 0.922 |
| Sex | |||
| • Female | 56 (69.1%) | 73 (51.0%) | 0.008 |
| • Male | 25 (30.9%) | 70 (49.0%) | |
| Overall adherencea, n (%) | 17 (21.0%) | 30 (20.8%) | 0.978 |
| Time to follow-up CTb, mean mos ± SD | 15.3 ± 4.8 | 12.7 ± 2.3 | 0.015 |
| Timely adherencec, n (%) | 4 (23.5%) | 11 (57.9%) | 0.002 |
a Overall adherence was defined as any follow-up CT chest following the baseline LDCT
b Time to follow-up was measured among screened patients who were adherent with any follow-up CT
c On-time adherence was defined as a follow-up CT within 30 days of the recommended time-frame for follow-up (13 months for Lung-RADS 1 or 2)